AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMMUTEP LTD

0.053

-0.001-1.85%

Volume:4.32M

Turnover:229.63K

Market Cap:78.11M

PE:-0.93

High:0.055

Open:0.053

Low:0.052

Close:0.054

52wk High:0.470

52wk Low:0.028

Shares:1.47B

Float Shares:1.23B

Volume Ratio:0.80

T/O Rate:0.35%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.057

EPS(LYR):-0.042

ROE:-61.85%

ROA:-32.10%

PB:0.79

PE(LYR):-1.26

Loading ...

Overview Company News Filings

Immutep Says Eftisarc-neo Phase II Eposter on Efti Hrqol in Soft Tissue Sarcoma Accepted for ESMO 2026

Immutep Receives New US Patent for Cancer Treatment Method; Shares Down 4%

MT Newswires Live

Immutep Provides Clinical Update in 1st Line Nsclc: Positive Mature Overall Survival Data from Insight-003 and Update from Tacti-004

THOMSON REUTERS

Immutep - Insight-3 Shows Mature Median Overall Survival of 30.9 Months in 1L Non-squamous Nsclc

THOMSON REUTERS

Immutep - Tacti-4 Root Cause Analysis Ongoing, Results Expected Q3 Cy2026

THOMSON REUTERS

Immutep - no New Safety Signals Observed to Date in Tacti-4

THOMSON REUTERS

Immutep Says Median Overall Survival 30.9 Months for Non-Small Cell Lung Cancer Patients in Phase One Trial

MT Newswires Live

ASX Penny Stocks: Immutep And Two More Companies To Watch

Simply Wall St.

Here's Why We're Watching Immutep's (ASX:IMM) Cash Burn Situation

Simply Wall St.

Immutep Raised to Buy From Hold by Maxim Group

Immutep Ltd : Maxim Group Raises to Buy From Hold

THOMSON REUTERS

Immutep Says JPMorgan Ceases to Be Substantial Holder

MT Newswires Live

Immutep Says First-in-Human Study Assessing Autoimmune Disease Drug Candidate Meets Primary Endpoint; Shares Down 4%

MT Newswires Live

Immutep reports positive interim Phase I data for autoimmune drug candidate IMP761 at EULAR 2026

Immutep - Efti + Soc Shows Median Overall Survival Improvement of 7.7 Months in Alc Responders

THOMSON REUTERS

Immutep - Announces Results From 5 Clinical Trials of Eftilagimod Alfa in Late-Stage Cancer

THOMSON REUTERS

Immutep Reports Survival Benefit Linked to Immune Response in Efti Clinical Trial Analysis

MT Newswires Live

Immutep says eftilagimod alfa plus standard care boosts overall survival in late-stage cancer study analysis

Immutep executives face securities class action after ADRs plunge 83% on trial collapse

Immutep Receives Nasdaq Notice of Bid Price Deficiency

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/IMM.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.053,"timestamp":1787292720000,"preClose":0.054,"halted":0,"volume":4321750,"delay":0,"changeRate":-0.018518518518518535,"nameEN":"IMMUTEP LTD","floatShares":1228247159,"shares":1473721306,"eps":-0.057294,"marketStatus":"Not Yet Opened","change":-0.001,"latestTime":"08-21 16:12:00 AEST","open":0.053,"high":0.055,"low":0.052,"amount":229631,"amplitude":0.055556,"askPrice":0.053,"askSize":632996,"bidPrice":0.052,"bidSize":1000000,"shortable":3,"etf":0,"ttmEps":-0.057294,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.054,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":0.7975004793391139,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IMM.AU","preClose":0.054,"auctionPrice":0.053,"auctionVolume":532478,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292600774}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1228247159,"roa":"-32.10%","roe":"-61.85%","lyrEps":-0.042199,"volumeRatio":0.7975004793391139,"shares":1473721306,"dividePrice":0,"high":0.055,"amplitude":0.055556,"preClose":0.054,"low":0.052,"week52Low":0.028,"pbRate":"0.79","psRate":"9.86","week52High":0.47,"institutionHeld":0,"latestPrice":0.053,"committee":0.224743,"eps":-0.057294,"divideRate":0,"volume":4321750,"delay":0,"ttmEps":-0.057294,"open":0.053,"prevYearClose":0.415,"prevWeekClose":0.053,"prevMonthClose":0.046,"prevQuarterClose":0.053,"fiveDayClose":0.052,"twentyDayClose":0.048,"sixtyDayClose":0.053,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2653084916","title":"Immutep Says Eftisarc-neo Phase II Eposter on Efti Hrqol in Soft Tissue Sarcoma Accepted for ESMO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2653084916","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653084916?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:05","pubTimestamp":1784894709,"startTime":"0","endTime":"0","summary":"Immutep says EFTISARC-NEO Phase II ePoster on efti HRQoL in soft tissue sarcoma accepted for ESMO 2026Immutep flagged an accepted ESMO Congress 2026 ePoster from the Phase II EFTISARC-NEO trial of eft","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDL3Nl1BT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651126444","title":"Immutep Receives New US Patent for Cancer Treatment Method; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651126444","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651126444?lang=en_us&edition=fundamental","pubTime":"2026-07-14 11:25","pubTimestamp":1783999558,"startTime":"0","endTime":"0","summary":"Immutep  obtained a fourth patent from the US Patent and Trademark Office related to its cancer treatments, according to a Tuesday filing with the Australian bourse.The new patent, which covers methods to treat cancer by administering eftilagimod alfa in combination with PD-1 pathway inhibitors, has an expiry date of Jan. 20, 2036, per the filing.The company is evaluating eftilagimod alfa in a variety of solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, soft tissue sarcoma, and breast cancer.Immutep shares fell nearly 4% in recent Tuesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651811966","title":"Immutep Provides Clinical Update in 1st Line Nsclc: Positive Mature Overall Survival Data from Insight-003 and Update from Tacti-004","url":"https://stock-news.laohu8.com/highlight/detail?id=2651811966","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651811966?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:00","pubTimestamp":1783944003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUA2HW17Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651196131","title":"Immutep - Insight-3 Shows Mature Median Overall Survival of 30.9 Months in 1L Non-squamous Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2651196131","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651196131?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:00","pubTimestamp":1783944003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUA2HW17Z:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651119690","title":"Immutep - Tacti-4 Root Cause Analysis Ongoing, Results Expected Q3 Cy2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2651119690","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651119690?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:00","pubTimestamp":1783944003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUA2HW17Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651119615","title":"Immutep - no New Safety Signals Observed to Date in Tacti-4","url":"https://stock-news.laohu8.com/highlight/detail?id=2651119615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651119615?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:00","pubTimestamp":1783944003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUA2HW17Z:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651819633","title":"Immutep Says Median Overall Survival 30.9 Months for Non-Small Cell Lung Cancer Patients in Phase One Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651819633","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651819633?lang=en_us&edition=fundamental","pubTime":"2026-07-13 14:36","pubTimestamp":1783924582,"startTime":"0","endTime":"0","summary":"Immutep  said the median overall patient survival was 30.9 months in patients in its INSIGHT-003 phase one trial, evaluating eftilagimod alfa, or efti, in combination with Merck's anti-PD-1 therapy Keytruda, or pembrolizumab, and chemotherapy as first-line therapy for advanced or metastatic non-small cell lung cancer in 51 evaluable non-squamous patients, according to a Monday Australian bourse filing.Around 92% of patients enrolled in the trial had no or low programmed death-ligand 1  expression, with a tumor proportion score under 50%. The median overall survival was 37.8 months in patients with a tumor proportion score of over 50%.The results compare favorably with historical benchmarks, the filing said.Preliminary immune monitoring data generated from its discontinued TACTI-004 phase three trial indicated that patients treated with efti showed a different immune activation profile compared with those observed in previous studies. The TACTI-004 analysis is ongoing, with additional r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645856336","title":"ASX Penny Stocks: Immutep And Two More Companies To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2645856336","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645856336?lang=en_us&edition=fundamental","pubTime":"2026-06-24 03:02","pubTimestamp":1782241379,"startTime":"0","endTime":"0","summary":"The Australian market is poised for a 20-point advance at open, reflecting global optimism despite recent tech sector jitters overseas. While the term 'penny stocks' might seem outdated, these smaller or newer companies still hold significant potential when supported by strong financials. In this article, we explore three promising penny stocks that combine balance sheet strength with growth opportunities, offering investors a chance to uncover hidden value in quality companies.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/3021000-choice1-main-header/1585186644732","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3021000-choice1-main-header/1585186644732"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/capital-goods/asx-oec/orbital-shares/news/asx-penny-stocks-immutep-and-two-more-companies-to-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/capital-goods/asx-oec/orbital-shares/news/asx-penny-stocks-immutep-and-two-more-companies-to-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","TCG.AU","BK7506","IMM.AU","BK7115","BK7508","OEC.AU","BK7104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644061818","title":"Here's Why We're Watching Immutep's (ASX:IMM) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2644061818","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644061818?lang=en_us&edition=fundamental","pubTime":"2026-06-20 04:03","pubTimestamp":1781899385,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-imm/immutep-shares/news/heres-why-were-watching-immuteps-asximm-cash-burn-situation","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-imm/immutep-shares/news/heres-why-were-watching-immuteps-asximm-cash-burn-situation","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644744422","title":"Immutep Raised to Buy From Hold by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2644744422","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644744422?lang=en_us&edition=fundamental","pubTime":"2026-06-17 22:23","pubTimestamp":1781706180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 17, 2026 10:23 ET (14:23 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMMP","IMM.AU","BK4139","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644745390","title":"Immutep Ltd : Maxim Group Raises to Buy From Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644745390?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:56","pubTimestamp":1781697414,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nFWN42P0DZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMP","BK7508","IMM.AU","BK7067","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642417302","title":"Immutep Says JPMorgan Ceases to Be Substantial Holder","url":"https://stock-news.laohu8.com/highlight/detail?id=2642417302","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642417302?lang=en_us&edition=fundamental","pubTime":"2026-06-10 12:53","pubTimestamp":1781067196,"startTime":"0","endTime":"0","summary":"Immutep  said JPMorgan Chase & Co. and its affiliates ceased to be substantial holders of the company on June 5, according to a Wednesday Australian bourse filing.JPMorgan Chase & Co. and its affiliates became substantial holders on June 3 with a 5.2% voting power, an earlier filing showed.Immutep's shares were down past 2% in recent Wednesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0211326839.USD","BK4534","IE0034235303.USD","LU0787776722.HKD","BK7067","JPX","IE00BLSP4239.USD","LU2106854487.HKD","LU1064131342.USD","IE00BDRTCR15.USD","LU2237443549.SGD","BK4588","LU0106261372.USD","LU1162221912.USD","SG9999002224.SGD","LU2430703251.USD","LU0820561818.USD","BK4504","LU1084165304.USD","IE00B3S45H60.SGD","IMM.AU","BK4516","LU1366192091.USD","PGF","JPO","IE0034235295.USD","LU1894683264.USD","LU2237443465.HKD","LU0345770308.USD","JPMO","LU0820561909.HKD","IE00BJTD4V19.USD","LU0211331839.USD","LU1116320737.USD","IE00BN8TJ469.HKD","LU0868494708.USD","LU0211326755.USD","IE00BLSP4452.SGD","LU0496365809.HKD","LU2023250843.SGD","LU2746668974.SGD","LU2505996509.AUD","IE00BJLML261.HKD","LU2023250504.SGD","LU1670628061.USD","JPM","LU2552382215.SGD","LU2054465674.USD","BK4585","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640298135","title":"Immutep Says First-in-Human Study Assessing Autoimmune Disease Drug Candidate Meets Primary Endpoint; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640298135","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640298135?lang=en_us&edition=fundamental","pubTime":"2026-06-04 10:06","pubTimestamp":1780538771,"startTime":"0","endTime":"0","summary":"Immutep  said a first-in-human phase one study evaluating IMP761, a potential therapeutic option for autoimmune diseases, met its primary endpoint, showing favorable safety and tolerability in healthy volunteers in the single ascending dose part of the study, according to a Thursday filing with the Australian bourse.IMP761 was designed to target activated T cells at inflammation sites to reduce pathological immune responses while preserving systemic immune function, the filing said.Early findings showed \"significant and clinically relevant\" pharmacodynamic activity, including the reduction of local inflammatory responses and attenuated T-cell activity compared with placebo across groups ranging from 0.9 milligrams per kilogram to 7 milligrams per kilogram, per the filing.Shares fell nearly 4% in morning trade Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640737180","title":"Immutep reports positive interim Phase I data for autoimmune drug candidate IMP761 at EULAR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640737180","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640737180?lang=en_us&edition=fundamental","pubTime":"2026-06-04 08:11","pubTimestamp":1780531906,"startTime":"0","endTime":"0","summary":"Immutep flagged positive interim Phase I data for autoimmune candidate IMP761, with results set for presentation at EULAR 2026 on June 4.The first-in-human trial in healthy volunteers met its primary goal, showing favorable safety and tolerability.Early readouts showed pharmacodynamic activity consistent with immunosuppressive effects versus placebo, supporting further development in autoimmune disease.The pharmacokinetic profile supports dosing about once every four weeks, shaping the program’s Phase II planning.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL3NVp6T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698766","title":"Immutep - Efti + Soc Shows Median Overall Survival Improvement of 7.7 Months in Alc Responders","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698766","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698766?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:10","pubTimestamp":1779970241,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nFWN4250NC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698713","title":"Immutep - Announces Results From 5 Clinical Trials of Eftilagimod Alfa in Late-Stage Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698713","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698713?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:10","pubTimestamp":1779970241,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nFWN4250NC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638365224","title":"Immutep Reports Survival Benefit Linked to Immune Response in Efti Clinical Trial Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2638365224","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638365224?lang=en_us&edition=fundamental","pubTime":"2026-05-28 13:56","pubTimestamp":1779947778,"startTime":"0","endTime":"0","summary":"Immutep  said a systematic evaluation of five clinical trials of eftilagimod alfa , an antigen-presenting cell  activator, in combination with standard-of-care therapies in late-stage cancer patients showed a significant increase in circulating absolute lymphocyte count  compared to standard-of-care alone, according to a Thursday Australian bourse filing.The company said increased ALC was significantly associated with improved clinical outcomes, with ALC responders in the efti plus standard-of-care group showing a clinically meaningful median overall survival improvement of 7.7 months compared to ALC non-responders, with no corresponding association observed in the standard-of-care alone group.\"The findings link the immune-activating effect of efti measured in patients' blood with meaningful and significant survival improvements observed in previous clinical trials,\" said Immutep's Chief Scientific Officer, Frederic Triebel, adding that the studies highlighted a key connection with eft","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1935043536.SGD","LU2236285917.USD","LU1935042991.SGD","IMM.AU","BK7067","LU1718418525.SGD","LU1366192091.USD","ALC.AU","LU1496350171.SGD","BK4214","BK4198","BK4534","BK7508","BK7094","LU0053666078.USD","LU1066051811.HKD","BK7095","LU0157215616.USD","LU2417539215.USD","LU1935042488.USD","LU2237443978.SGD","LU1778281490.HKD","LU2083900584.USD","LU2456880835.USD","LU0314104364.USD","LU1935042215.USD","APC","ALC","LU0149725797.USD","LU1674673691.USD","LU2237443622.USD","LU2265009873.SGD","LU2420271590.USD","LU1066051498.USD","LU2237443382.USD","LU1366333091.USD","LU0170899867.USD","APC.AU","LU0077335932.USD","LU0786609619.USD","LU1674673428.USD","LU0882574139.USD","LU1066053197.SGD","LU1935043023.USD","LU2237443549.SGD","LU1066051225.USD","LU1804176565.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638658881","title":"Immutep says eftilagimod alfa plus standard care boosts overall survival in late-stage cancer study analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2638658881","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638658881?lang=en_us&edition=fundamental","pubTime":"2026-05-28 09:04","pubTimestamp":1779930262,"startTime":"0","endTime":"0","summary":"Immutep disclosed a pooled evaluation of five eftilagimod alfa combination trials in late-stage cancers, linking immune activation to better survival outcomes.Patients showing a treatment-related immune response tended to live longer than non-responders, a pattern not seen with standard therapy alone.Findings were consistent across multiple tumor types and across combinations with chemotherapy or PD-1-based immunotherapy.The analysis excluded the discontinued TACTI-004 Phase III lung cancer trial, limiting read-through to earlier-stage studies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contain","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL9l2P64:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333915","title":"Immutep executives face securities class action after ADRs plunge 83% on trial collapse","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333915","media":"Reuters","labels":["executive","policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637333915?lang=en_us&edition=fundamental","pubTime":"2026-05-21 21:08","pubTimestamp":1779368914,"startTime":"0","endTime":"0","summary":"Immutep faces a securities class action tied to investor purchases from March 24, 2025 to March 12, 2026, centered on the collapse of the TACTI-004 trial.ADRs fell to $0.48 from $2.76 on March 13, 2026, a one-day drop of 83% that erased $2.28 per share.The suit names CEO Marc Voigt, Chief Scientific Officer Frédéric Triebel, and Chief Medical Officer Stephan Winckels as individual defendants under Section 20 control-person claims.Plaintiffs allege the executives misled investors about trial progress while holding adverse non-public interim data, including through Sarbanes-Oxley certifications tied to SEC filings.A court deadline of July 6, 2026 has been set for investors seeking appointment as lead plaintiff.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL3s7WXt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Immutep executives face securities class action after ADRs plunge 83% on trial collapse","news_tag":"executive,policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631090631","title":"Immutep Receives Nasdaq Notice of Bid Price Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2631090631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631090631?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:00","pubTimestamp":1777550406,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUA5TB9FC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":81,"code":"91000000","status":"200"}]}}